Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085335 | 0.99 | BRD4 (0.42) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3093529 | 0.99 | BRD4 (0.42) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3089419 | 0.82 | BRD4 (0.42) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3086306 | 0.81 | BRD4 (0.43) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3077997 | 0.81 | BRD4 (0.43) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3093485 | 0.80 | BRD4 (0.42) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3080828 | 0.79 | KMT2A (0.49) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3086066 | 0.78 | BRD4 (0.43) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3082410 | 0.78 | BRD4 (0.43) | BRD4ALDH1A1BRD2BRD3BRDT | |
| SCHEMBL3090110 | 0.78 | BRD4 (0.43) | BRD4ALDH1A1BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| WO-2008129075-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS | TOPOTARGET A/S (DK) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TPH2, TPH1, HTR2C | BRD4 616/4885ALDH1A1 360/4885BRD2 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.